Tecentriq® (atezolizumab) – Expanded indication
December 4, 2019 - Roche announced the FDA approval of Tecentriq (atezolizumab), in combination with Abraxane® (paclitaxel protein-bound) and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
Top